Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Insulin pump users face less risk of dying from cardiovascular disease

People with type 1 diabetes who use insulin pump therapy face almost 50% less risk of dying from cardiovascular disease than those who take insulin by multiple daily injections. The British Medical Journal has published a study conducted at Sahlgrenska Academy.

12 Aug 2015

Trans fats associated with greater risk of death, coronary heart disease

A study led by researchers at McMaster University has found that that trans fats are associated with greater risk of death and coronary heart disease, but saturated fats are not associated with an increased risk of death, heart disease, stroke, or Type 2 diabetes.

12 Aug 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

7 Aug 2015

Scientists publish new important clues about marrow fat

While most of us worry about the fat cells building up on the fleshy parts of our bodies, scientists have started to pay serious attention to another kind of fat cell deep inside our bones, in what's called the marrow.

7 Aug 2015

BIDMC scientists discover new vitamin B3 pathway that regulates liver metabolism

Researchers at Beth Israel Deaconess Medical Center have identified a new vitamin B3 pathway that regulates liver metabolism. The discovery provides an opportunity to pursue the development of novel drug therapies to address obesity, type 2 diabetes and related metabolic diseases.

7 Aug 2015

Researchers show how microbiota protects against type 1 diabetes development

Our bodies have ten times the amount of microbes than human cells. This set of bacteria is called microbiota. In some instances, bacteria known as pathogens can cause infectious diseases. However, these micro-organisms can also protect us from certain diseases. Researchers from Inserm, Paris Descartes University and the CNRS (French National Centre for Scientific Research), through collaboration with teams from China and Sweden, have recently shown how microbiota protects against the development of type 1 diabetes.

7 Aug 2015

Metformin drug has impact on blood fat levels

Besides affecting the blood sugar levels, the substance Metformin, also has an impact on blood fat levels. This was elucidated by an interdisciplinary team of the German Center for Diabetes Research headed by Dr. Rui Wang-Sattler of the Helmholtz Zentrum München. Especially the harmful LDL cholesterol can be reduced.

6 Aug 2015

Certain genes exposed to harsh environmental factors can increase diabetes risk

Arsenic, which can be present in ground water, modifies an enzyme that alters the secretion of insulin in the pancreas. Physicians, usually, show type II diabetes as a consequence of an exaggerated food intake and lack of exercise; however, there are about 50 genes that cause changes in the DNA, known as polymorphisms, that when combined with harsh environmental factors are at increased risk of developing the disease, mentioned PhD Marta Ostrosky Wegman, director of the Institute for Biomedical Research the National University of Mexico (UNAM).

5 Aug 2015

Findings by Joslin scientists may lead to early detection, treatment of complications in type 1 diabetes

Joslin scientists have advanced understanding of how the cellular repair process is impaired in type 1 diabetes, which can cause cell death and lead to complications. The findings appear in the August issue of Cell Metabolism.

5 Aug 2015

BrightFocus announces recipients of 2015 research program grants

BrightFocus Foundation, which funds research worldwide on Alzheimer's disease, glaucoma, and macular degeneration, today announced that its 2015 research program grants have been awarded to 58 scientists in 20 states and 7 foreign countries. Part of an $11 million research investment, the grants reflect the largest annual research funding in the foundation's history.

4 Aug 2015

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the Russian Federation for patent applications numbered 11766702.2-1460 and 2012147449, respectively.

3 Aug 2015

Consuming alcohol at conception increases diabetes risk in offspring

Babies conceived by women who drink alcohol around the time of conception face dramatically increased risks of type 2 diabetes and obesity in early middle age, a University of Queensland study has found.

3 Aug 2015

Integrated treatment required for diabetes-eating disorder combination

As they reach their teens, many with type 1 diabetes discover that the disease provides a secret weapon for losing weight. By restricting or reducing the amount of insulin they inject, they can eat just about anything they want and control their weight.

3 Aug 2015

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up.

31 Jul 2015

New research shows promising progress in use of anti-inflammatory cytokine for T1D treatment

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports (Nature Publishing Group), reveals that administration of interleukin-35 (a protein made by immune cells) to mice with type 1 diabetes, reverses or cures the disease by maintaining a normal blood glucose level and the immune tolerance.

30 Jul 2015

Bioenergetic analysis of pancreatic beta-cells shows impaired metabolic signature in type 2 diabetes patients

Impaired activation of mitochondrial energy metabolism in the presence of glucose has been demonstrated in pancreatic beta-cells from patients with type 2 diabetes. The cause of this dysfunction has been unknown. Publishing online in Endocrinology, Buck Institute assistant research professor Akos Gerencser, PhD, shows that in patients with type 2 diabetes the balance between supply and demand of the mitochondrial membrane potential (ΔψM) is altered causing a decrease in the signaling that turns on insulin secretion.

30 Jul 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

Low blood level of 4 proteins can help diabetics protect against immune attack

Patients with type 1 diabetes have significantly lower blood levels of four proteins that help protect their tissue from attack by their immune system, scientists report.

30 Jul 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

IOF, EOS to jointly hold Middle East & Africa Osteoporosis Meeting in Abu Dhabi

With a growing senior population and an increase in unhealthy lifestyles, the prevalence of osteoporosis and Type 2 Diabetes Mellitus is soaring in the Middle East and North African region. In response to the dramatic increase in these diseases within the region the International Osteoporosis Foundation, in cooperation with the Emirates Osteoporosis Society, will be holding the 3rd Middle East & Africa Osteoporosis Meeting from December 5-7, 2015 in Abu Dhabi.

29 Jul 2015

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Insulin pump users face less risk of dying from cardiovascular disease

Trans fats associated with greater risk of death, coronary heart disease

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Scientists publish new important clues about marrow fat

BIDMC scientists discover new vitamin B3 pathway that regulates liver metabolism

Researchers show how microbiota protects against type 1 diabetes development

Metformin drug has impact on blood fat levels

Certain genes exposed to harsh environmental factors can increase diabetes risk

Findings by Joslin scientists may lead to early detection, treatment of complications in type 1 diabetes

BrightFocus announces recipients of 2015 research program grants

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

Consuming alcohol at conception increases diabetes risk in offspring

Integrated treatment required for diabetes-eating disorder combination

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

New research shows promising progress in use of anti-inflammatory cytokine for T1D treatment

Bioenergetic analysis of pancreatic beta-cells shows impaired metabolic signature in type 2 diabetes patients

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Low blood level of 4 proteins can help diabetics protect against immune attack

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

IOF, EOS to jointly hold Middle East & Africa Osteoporosis Meeting in Abu Dhabi

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in